Notice for International Patients & Caregivers

English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.

Provincial Landscape

Snapshot: 2026-09-04

Sichuan Multiple Myeloma Active Trials & Centers

As of 2026-09-04, there are 21 active clinical trials for multiple myeloma hosted across 11 tertiary medical centers in Sichuan (including Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Affiliated Hospital of North Sichuan Medical College, West China Hospital of Sichuan University, etc.).

Active Trials

Hospitals

Therapies

CAR-T Cell Therapy / Bispecific & Multispecific Antibodies / Monoclonal Antibodies / Oral Small-Molecule Agents

Participating Medical Centers (11)

Sichuan Academy of Medical Sciences & Sichuan Provincial People's HospitalAffiliated Hospital of North Sichuan Medical CollegeWest China Hospital of Sichuan UniversityYibin Second People's HospitalSichuan Provincial People's HospitalMianyang Central Hospital西南医科大学附属医院Chengdu Shangjin Nanfu HospitalChengdu Second People's HospitalSichuan Cancer HospitalThe Third People's Hospital of Chengdu

Active Studies in Sichuan (21)

Population synthesized by CMDN

Showing 0 published English records of 21 registry trials.

All 21 local registry studies currently have Chinese-only filings. Verified English summaries will be published upon regulatory audit.

Back to National Landscape Filter Local Trials in the Trial Hub